MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-05-2026
Arrowhead Pharmaceuticals ROA Ratio 2011-2026 | ARWR
Annual ROA Ratio Arrowhead Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.12 | -52.6 | -26.81 | -25.44 | -19.83 | -16.18 | 19.43 | -48.79 | -33.05 | -63.76 | -69.51 | -32.07 | -83.43 | -127.82 | -19.69 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.43 | -127.82 | -39.98 |
Quarterly ROA Ratio Arrowhead Pharmaceuticals
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -40.54 | -49.09 | -68.42 | -68.84 | -53.66 | -66.59 | -60.2 | -41.62 | -12.11 | -12.11 | 7.13 | 7.98 | 2.77 | -7.61 | -11.68 | -21.77 | -12.0 | -18.91 | -17.45 | -17.64 | -13.94 | 9.06 | 17.47 | 20.68 | 24.66 | -30.57 | -50.36 | -38.81 | -57.3 | -28.48 | -19.8 | -36.39 | -29.81 | -36.83 | -46.68 | -57.11 | -66.02 | -67.4 | -64.29 | -62.62 | -59.25 | -52.81 | -47.12 | -44.9 | -42.45 | -66.85 | -76.78 | -92.9 | -111.73 | -170.72 | -202.79 | -202.23 | -182.72 | -802.7 | -765.81 | -753.53 | -715.66 | -11.45 | -15.64 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 24.66 | -802.7 | -95.17 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ACADIA Pharmaceuticals
ACAD
|
19.07 | $ 22.5 | 1.86 % | $ 3.73 B |  USA |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 327.16 | 2.39 % | $ 42.9 B | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Amgen
AMGN
|
8.51 | $ 349.22 | 2.71 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.18 | 1.33 % | $ 447 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.57 | 5.59 % | $ 3.13 B | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.48 | 8.46 % | $ 394 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.85 | 2.41 % | $ 9.26 B |  Australia |
 |
BioNTech SE
BNTX
|
65.02 | $ 91.76 | 2.39 % | $ 27.2 B | Germany |
 |
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.71 | 5.51 % | $ 17 M | USA |
 |
Avid Bioservices
CDMO
|
-41.82 | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-79.06 | - | - | $ 1.41 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-86.4 | $ 3.06 | 0.99 % | $ 6.66 B | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 3.06 | -0.33 % | $ 307 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | USA |
 |
Cerus Corporation
CERS
|
-7.04 | $ 1.9 | 2.99 % | $ 362 M | USA |
 |
Coherus BioSciences
CHRS
|
65.04 | $ 1.7 | 1.8 % | $ 199 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-88.77 | $ 0.36 | 0.28 % | $ 4.12 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
-48.42 | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
19.41 | $ 25.57 | 2.3 % | $ 3.13 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
-73.85 | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-36.63 | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
-145.48 | $ 2.81 | 2.18 % | $ 7.33 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-41.16 | - | - | $ 2.18 B | USA |